Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0794
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2618
    -0.0004 (-0.03%)
     
  • USD/JPY

    151.3290
    -0.0430 (-0.03%)
     
  • Bitcoin USD

    70,192.76
    -637.19 (-0.90%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,369.44
    +201.37 (+0.50%)
     

Cyclo Therapeutics' Trappsol Shows Early Safety, Efficacy In Genetic Disorder

  • Cyclo Therapeutics Inc (NASDAQ: CYTH) has announced new data from its Phase 1 extension study evaluating Trappsol Cyclo Niemann-Pick Disease Type C1 (NPC), a genetic disorder characterized by the abnormal accumulation of cholesterol in cells.

  • Efficacy as measured NPC Severity Scale showed a trend of stability for patients, with the mean length of exposure of 25 months.

  • Using a sub-set of NPC Severity Scale, assessing the quality of life (Speech, Swallow, Fine Motor skills, Ambulation and Cognition), a trend in disease stabilization was observed.

  • An average worsening of 0.4 pts per year was observed for all patients with all available data. It is significant as a worsening of 1.4 pts per year would be expected for NPC patients based on published calculations.

  • The patient who improved overall in the 5-Domain NPC Severity Score received the 1500 mg/kg dose, while the patient who worsened overall also received the 1500 mg/kg dose.

  • Of the 3 patients who were stable overall, 2 received the 1500 mg/kg dose, and 2 received the 2500 mg/kg dose.

  • Trappsol Cyclo is a proprietary formulation of hydroxypropyl beta-cyclodextrin, which has an affinity for cholesterol. The candidate is currently in a pivotal Phase 3 study.

  • Price Action: CYTH stock is down 0.5% at $8.31 during the market session on the last check Friday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement